Shilpa Medicare logo

SHILPAMED - Shilpa Medicare Share Price

₹631 4.5  0.7%

Last Trade - 6:55am

Mid Cap
Market Cap £524.7m
Enterprise Value £552.6m
Revenue £93.3m
Position in Universe 325th / 3000
Unlock SHILPAMED Revenue
Relative Strength (%)
1m +20.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -9.85%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
6,138 7,222 7,838 7,915 7,334 9,079 10,572 12,050 +8.1%
-5.0 +44.7 -0.6 -6.6 +21.9 +21.6 +22.2 +19.7
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 30 June 2020, Shilpa Medicare Ltd revenues increased 38% to RS2.23B. Net income applicable to common stockholders increased from RS157.4M to RS863.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Exceptional items before tax increase from RS0K to RS608.4M (income), Other Income increase from RS19.8M to RS54.8M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SHILPAMED
Graphical History


SHILPAMED Revenue Unlock SHILPAMED Revenue

Net Income

SHILPAMED Net Income Unlock SHILPAMED Revenue

Normalised EPS

SHILPAMED Normalised EPS Unlock SHILPAMED Revenue

PE Ratio Range

SHILPAMED PE Ratio Range Unlock SHILPAMED Revenue

Dividend Yield Range

SHILPAMED Dividend Yield Range Unlock SHILPAMED Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SHILPAMED EPS Forecasts Unlock SHILPAMED Revenue
Profile Summary

Shilpa Medicare Limited is engaged in the business of manufacturing of bulk drugs or active pharmaceutical ingredient (API) and intermediates, and wind power generation. The Company's segments include Bulk Drug/Intermediates and Energy. It offers 3a 7b Dihydroxy. The Company deals with APIs, Intermediates, Formulations, New Drug Delivery Systems, Peptides/Biotech products and Specialty Chemicals. The Company supplies oncology/non-oncology APIs and intermediates. Its oncology API products include Anastrozole, Axitinib, Azacitidine, Abiraterone Acetate, Bicalutamide, Bortezomib, Busulphan, Cabazitaxel Amorphous, Capecitabine, Carboplatin, Cladribine, Clofarabine, Zoledronic acid, Vismodegib, Pemetrexed DiPotassium Nonahydrate, Cyclophosphamide Monohydrate and Cytarabine. It also offers AntiRetroVirals. Its non-oncology API products include Acebrophylline, Echothiophate, Nifedipine, Perfenidone, PrucaloprideSuccinate, Sildenafil Citrate, Ursodeoxycholic acid and Dimethyl Fumarate.

Last Annual March 31st, 2020
Last Interim March 31st, 2020
Incorporated November 20, 1987
Public Since March 31, 1995
No. of Shareholders: n/a
No. of Employees: 1,781
Sector Healthcare
Industry Pharmaceuticals
Exchange National Stock Exchange of India
Shares in Issue 81,527,000
Free Float (0.0%)
Eligible for
SHILPAMED Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SHILPAMED
Upcoming Events for SHILPAMED
Frequently Asked Questions for Shilpa Medicare
What is the Shilpa Medicare share price?

As of 6:55am, shares in Shilpa Medicare are trading at ₹631, giving the company a market capitalisation of £524.7m. This share price information is delayed by 15 minutes.

How has the Shilpa Medicare share price performed this year?

Shares in Shilpa Medicare are currently trading at ₹631 and the price has moved by 88.41% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Shilpa Medicare price has moved by 81.58% over the past year.

What are the analyst and broker recommendations for Shilpa Medicare?

Of the analysts with advisory recommendations for Shilpa Medicare, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Shilpa Medicare is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Shilpa Medicare next release its financial results?

Shilpa Medicare is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Shilpa Medicare dividend yield?

Shilpa Medicare does not currently pay a dividend.

Does Shilpa Medicare pay a dividend?

Shilpa Medicare does not currently pay a dividend.

When does Shilpa Medicare next pay dividends?

Shilpa Medicare does not currently pay a dividend.

How do I buy Shilpa Medicare shares?

To buy shares in Shilpa Medicare you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Shilpa Medicare?

Shares in Shilpa Medicare are currently trading at ₹631, giving the company a market capitalisation of £524.7m.

Where are Shilpa Medicare shares listed? Where are Shilpa Medicare shares listed?

Here are the trading details for Shilpa Medicare:

Country of listing: India
Exchange: NSI
Ticker Symbol: SHILPAMED
What kind of share is Shilpa Medicare?

Based on an overall assessment of its quality, value and momentum, Shilpa Medicare is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Shilpa Medicare share price forecast 2020?

Shares in Shilpa Medicare are currently priced at ₹631. At that level they are trading at 10.62% premium to the analyst consensus target price of 0.00.

Analysts covering Shilpa Medicare currently have a consensus Earnings Per Share (EPS) forecast of 23.4 for the next financial year.

How can I tell whether the Shilpa Medicare share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shilpa Medicare. Over the past six months, the relative strength of its shares against the market has been 47.79%. At the current price of ₹631, shares in Shilpa Medicare are trading at 63.85% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Shilpa Medicare PE Ratio?

The Shilpa Medicare PE ratio based on its reported earnings over the past 12 months is 32.72. The shares are currently trading at ₹631.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Shilpa Medicare?

Shilpa Medicare's management team is headed by:

Omprakash Inani - NEC
Vishnukant Bhutada - MDR
Pramod Kasat - NID
Rajendra Reddy - NID
N. P. S. Shinh - NID
Carlton Pereira - NID
Sushil Bajaj - CFO
Piyush Goenka - IND
Who are the major shareholders of Shilpa Medicare?

Here are the top five shareholders of Shilpa Medicare based on the size of their shareholding:

Bhutada (Vishnukant C.) Individual Investor
Percentage owned: 11.56% (9.42m shares)
Baring Private Equity Asia Ltd. Private Equity
Percentage owned: 8.72% (7.11m shares)
Bhutada (Dharmavati) Individual Investor
Percentage owned: 7.61% (6.21m shares)
Tano Mauritius India FVCI II Corporation
Percentage owned: 7.58% (6.18m shares)
Inani (Ramakant) Individual Investor
Percentage owned: 4.6% (3.75m shares)
Similar to SHILPAMED
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.